title: Bisphosphonates-related osteonecrosis of the jaws: a preliminary study of salivary interleukins.
abstract: OBJECTIVE
  The aim of this preliminary study was analyze the possible alterations in some salivary interleukins, usually associated with the inflammatory processes.
  
  
  METHODS
  The study comprised three groups: group 1, with 26 cases with bisphosphonates-related osteonecrosis of the jaws (BRONJ). Group 2, with 29 patients who had received iBF but without BRONJ. Group 3, with 26 control patients not treated with BF and without oral lesions. We collected unstimulated whole saliva in all groups. A semiquantitative study was performed based on a cytokine array panel. We used the proteome profiler array for the study. We analyzed: Interleukin 1 alpha (IL-1α), interleukin-1 receptor antagonist (IL-1RA), and interleukin 1 beta (IL-1β).
  
  
  RESULTS
  We found higher salivary values for all the cytokines studied in group 1 than in group 2 and 3. IL-1β showed the major differences compared with control group. (P < 0.05)
  
  
  CONCLUSIONS
  This preliminary study confirms that there are alterations in these interleukins in patients with BRONJ. These results give support to further additional salivary studies on these biomarkers by quantitative measures.
authors.affiliation: Oral Medicine, Stomatology and Maxillofacial Surgery, Valencia University, University General Hospital, Valencia, Spain. bagan@uv.es
authors.forename: Jose
authors.initials: J
authors.lastname: Bagan
authors.forename: Chirag C
authors.initials: CC
authors.lastname: Sheth
authors.forename: Jose M
authors.initials: JM
authors.lastname: Soria
authors.forename: Maria
authors.initials: M
authors.lastname: Margaix
authors.forename: Leticia
authors.initials: L
authors.lastname: Bagan
mesh_terms: D015415:Biomarkers / Q000032:analysis; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000276:immunology*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007275:Injections, Intravenous; D053590:Interleukin 1 Receptor Antagonist Protein / Q000032:analysis*; D007375:Interleukin-1 / Q000032:analysis*; D053582:Interleukin-1alpha / Q000032:analysis; D053583:Interleukin-1beta / Q000032:analysis; D008297:Male; D008336:Mandibular Diseases / Q000276:immunology; D008439:Maxillary Diseases / Q000276:immunology; D008875:Middle Aged; D020543:Proteome / Q000032:analysis; D012463:Saliva / Q000276:immunology*; D012471:Salivary Proteins and Peptides / Q000032:analysis*; D000077211:Zoledronic Acid
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; C507763:IL1RN protein, human; D007093:Imidazoles; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D053582:Interleukin-1alpha; D053583:Interleukin-1beta; D020543:Proteome; D012471:Salivary Proteins and Peptides; D000077211:Zoledronic Acid